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Abstract
Background: The study of traditional knowledge of medicinal plants has led to discoveries that have helped combat
diseases and improve healthcare. However, the development of quantitative measures that can assist our quest for new
medicinal plants has not greatly advanced in recent years. Phylogenetic tools have entered many scientific fields in the last
two decades to provide explanatory power, but have been overlooked in ethnomedicinal studies. Several studies show that
medicinal properties are not randomly distributed in plant phylogenies, suggesting that phylogeny shapes ethnobotanical
use. Nevertheless, empirical studies that explicitly combine ethnobotanical and phylogenetic information are scarce.
Methodology/Principal Findings: In this study, we borrowed tools from community ecology phylogenetics to quantify
significance of phylogenetic signal in medicinal properties in plants and identify nodes on phylogenies with high
bioscreening potential. To do this, we produced an ethnomedicinal review from extensive literature research and a multi-
locus phylogenetic hypothesis for the pantropical genus Pterocarpus (Leguminosae: Papilionoideae). We demonstrate that
species used to treat a certain conditions, such as malaria, are significantly phylogenetically clumped and we highlight
nodes in the phylogeny that are significantly overabundant in species used to treat certain conditions. These cross-cultural
patterns in ethnomedicinal usage in Pterocarpus are interpreted in the light of phylogenetic relationships.
Conclusions/Significance: This study provides techniques that enable the application of phylogenies in bioscreening, but
also sheds light on the processes that shape cross-cultural ethnomedicinal patterns. This community phylogenetic approach
demonstrates that similar ethnobotanical uses can arise in parallel in different areas where related plants are available. With
a vast amount of ethnomedicinal and phylogenetic information available, we predict that this field, after further refinement
of the techniques, will expand into similar research areas, such as pest management or the search for bioactive plant-based
compounds.
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Introduction
Thousands of plant species are used in traditional medicine
around the globe, with almost one in four species on the planet
used in traditional medicine in some culture [1]. For decades
researchers have worked towards compiling a comprehensive list
of medicinal plant species from different regions around the world.
The documentation of such knowledge is crucial not only in order
to preserve it, but also to understand patterns that shape this
knowledge and to direct studies that can lead to the discovery of
new medicinal plants. Indeed, in the last decades, the field of
bioscreening has been guided by ethnomedicine, the study of
traditional medicine, leading to the discovery of several plant-
derived pharmaceuticals [2,3,4].
Medicinal properties are not randomly distributed in plants.
Instead, some plant groups are represented by more medicinal
plants than others [5,6,7,8,9]. Some of these studies suggested than
when looking for new medicinal plants, one should sample from
the ‘‘hot’’ groups, as they are more likely to deliver [7,9]. Although
this suggests that there is a phylogenetic pattern in medicinal
properties, these studies were not explicitly phylogenetic. Phylo-
genetic conservatism [10,11] in medicinal properties has been
proposed [12,13]. Lukhoba et al. [14] showed that for the genus
Plectranthus (Lamiaceae), with 62 of the 300 species used in some
sort of ethnomedicinal preparation, most medicinal species were
found within the same large phylogenetic clade, suggesting there is
a phylogenetic pattern in medicinal properties within the genus.
Although this was not quantified, a later study by Forest et al. [15]
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22275
used a more quantitative approach to show that in the Cape flora
of South Africa, ethnomedicinal plants were significantly clumped
on the phylogeny. A similar situation is observed in Narcissus
species with medicinal properties [13]. The reason for this non-
random phylogenetic distribution in medicinal properties might be
that closely related plant species share biochemistry [16] and
therefore, close relatives are likely to share medicinal properties.
The presumption of shared chemistry in close relatives gave rise to
the field of chemosystematics [17,18,19,20,21]. Nowadays taxon-
omies are no longer proposed based on chemical affinities; instead,
phylogeny provides a framework to understand the distribution of
chemistry. Combined phylogenetic and phytochemical studies
have shown that there is strong phylogenetic signal in the
distribution of chemical constituents in plants [22,23,24] that
can be applied in the research for novel natural products
[13,25,26,27]. However, chemical data are unavailable for the
majority of species and can be costly to generate. With less than a
quarter of plant species screened for bioactivity [28], explicit tools
are needed that can predict the phylogenetic position of species
with high potential. The emerging field, which we refer to here as
‘‘phylogenetic ethnobotany’’, still lacks quantitative metrics.
Biological phylogenies have proved to be extremely versatile
and valuable tools that have been applied in various fields, in order
to recover a variety of patterns, including biogeographical [29,30],
ecological [31,32,33], developmental [34], chemical [22,23] and
epidemiological [35]. With the exception of consideration of
phylogenetic patterns in biodiversity conservation [15,36,37] and
comparative sequence analyses to identify organisms (DNA
barcoding) [38,39,40,41], the potential of phylogenies to more
applied fields has been overlooked. Aside from the field of
bioscreening, phylogenetic patterns in medicinal plant use can
enrich our understanding of traditional ethnobotanical knowledge.
The finding that some plant lineages are more heavily used than
others [5,6,7,8,9] and the fact that there is a degree of agreement
in those lineages between disparate cultures [9,42,43] implies that
phylogenetic relationships underlie people’s selection of medicinal
plants in traditional medicine and in a fashion that overcomes
cultural differences. With the exception of some unpublished
studies presented at ethnobotanical conferences [44,45,46], such
findings have not been investigated in an explicitly phylogenetic
framework. By superposing medicinal properties on lineages with
wide distributions, one can observe cross-cultural phylogenetic
patterns in ethnobotany, such as the agreement in usage of closely
related lineages in distant cultures [44].
Pterocarpus is a pantropical genus of dalbergioid legumes. It has
been the subject of several regional taxonomic treatments
[47,48,49,50,51] and one monographic study by Rojo [52]. In
that study, Rojo recognised 20 species (23 taxa), but Lewis [53]
estimated this number as 25–30 species, not supporting Rojo’s
synonymisation of several taxa under the American species P.
rohrii. The most recent estimate is that of Klitgaard and Lavin [54],
where the number of species was estimated as 35–40. The main
centre of diversity of Pterocarpus is tropical Africa followed by the
Neotropics and Indomalaya [52], as shown in Figure 1. Several
Pterocarpus species are exploited throughout their range as timber as
well as in traditional medicine. As Klitgaard and Lavin [54] state,
the Indomalayan narra (P. indicus) is possibly one of the most
important timber legumes globally, and several African species are
very important timber trees known as paduak. The genus is used
medicinally across its range for a variety of conditions. Pterocarpus
species have received a lot of attention in recent years in
experimental studies that have provided evidence for their
bioactivity. Partly due to their extensive use, three species (P.
indicus, P. santalinus, P. marsupium) are listed under the IUCN Red
list of threatened species [55] and P. santalinus is also included in
CITES Annex II. Because of the wide range of documented
ethnomedicinal uses for Pterocarpus species, the evidence of
bioactivity for some of them, the critical status for some species
heavily affected by usage and the distribution of the genus across
three regions (Neotropics, tropical Africa and Indomalaya), it is an
ideal model group to develop approaches to study phylogenetic
patterns in medicinal properties.
Objectives
The objectives of the present study are to: i) compile information
from ethnobotanical sources to produce an ethnomedicinal review
of Pterocarpus from the literature across its geographic range, ii)
provide a phylogenetic hypothesis for the genus based on DNA
sequence data, iii) develop methods that allow more explicit use of
molecular phylogenetics in bioscreening, iv) highlight taxa that
could have medicinal properties and have been overlooked, based
on evidence from traditional medicine and the phylogeny and v)
explore cross-cultural ethnomedicinal patterns across the range of
the genus in light of phylogenetic relationships.
Figure 1. The pantropical distribution of Pterocarpus. Numbers indicate the numbers of taxa in different geographic regions; Neotropics,
Tropical Africa, Indomalaya (Indian Subcontinent and Malay Peninsula/Archipelago).
doi:10.1371/journal.pone.0022275.g001
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Materials and Methods
Ethnomedicinal information
Information on the medicinal uses of Pterocarpus species was
compiled from extensive literature research from 125 sources,
including published articles, online databases and local compendia
of traditional medicine. All literature sources are given in Table
S1. We collected information on the medicinal applications of
Pterocarpus species in traditional medicine throughout the range of
the genus, as well as pharmacological data from experimental
studies. These applications were subsequently organised in 13
categories of use following [56]: Circulatory/Blood, Gastro-
intestinal, Genito-urinary/Fertility, Infections/Fever, Inflamma-
tion, Musculo-Skeletal, Nervous, Pain, Poisons treatment, Respi-
ratory, Sensory, Skin and Unspecific.
Taxon sampling
Rojo [52] recognised 23 taxa in 20 species, but Lewis [53]
estimated this number to be 25–30 species, not supporting Rojo’s
synonymisation of several taxa under the American species P.
rohrii. Specifically, he recognised P. ternatus, P. villosus and P.
zehntneri as separate species from P. rohrii and we follow this
taxonomy here. We included all taxa recognised by Rojo [52]
(with the exception of the infraspecific taxon P. indicus forma
echinatus due to material unavailability), accepting the infraspecific
divisions of P. rotundifolius [57,58] and of P. mildbraedii [59], and
adding two neotropical taxa described after Rojo’s monographic
work, namely P. michelianus [60] and P. monophyllus [61]. This
brings the total taxa recognised in this study to 30 in 25 species.
Finally, we sampled several of the species that have been placed in
synonymy under the species complexes P. rohrii and P. tinctorius. All
Pterocarpus specimens included in the analyses are shown in Table
S2. Outgroups were selected from previous phylogenetic analyses
of dalbergioid legumes [62,63,64,65]. We sampled genera closely
related to Pterocarpus: Centrolobium, Grazielodendron, Inocarpus, Mar-
aniona, Ramorinoa, Tipuana. Platymisicum was used as external
outgroup taxon for the clade comprising these genera and
Pterocarpus and defined as such in all analyses. Outgroup accessions
are shown in Table S3.
Selection of DNA markers
We selected DNA markers based on amplification efficiency and
variability. We used the plastid regions rbcL and matK that have
shown great amplification efficiency across the angiosperms and
the legume family [66,67,68] and have been successfully amplified
and served as barcodes for two species of Pterocarpus in the
literature [39]. Additionally, we selected the ndhF-rpL32 intergenic
spacer, a plastid marker shown to be potentially one of the most
variable within the majority of angiosperm groups in a scan of the
plastid genome [69]. Finally, we amplified nrITS2 and the trnL-F
intergenic spacer, since these regions have provided phylogenetic
resolution for closely related genera in previous studies
[63,64,65,70].
DNA extraction and sequencing
Total DNA was extracted from 0.2 to 0.3 g of leaf and/or
flower tissue from herbarium or silica gel dried material using a
modification [71] of the Doyle and Doyle method [72]. DNA was
purified using QIAquick columns (Qiagen, Crawley, West Sussex,
UK) following the manufacturer’s protocol.
The internal transcribed spacer 2 (ITS2), including parts of the
5.8S ribosomal RNA gene and the 26S ribosomal RNA gene, was
amplified using primers ITS3 and ITS26E [73].The PCR protocol
included a 2 min initial denaturation at 96uC and 32 cycles of
1 min denaturation (96uC), 1 min annealing (48uC), 50 s elonga-
tion (72uC), with a final elongation of 7 min at 72uC. The trnL-F
intergenic spacer was amplified with primers ‘‘e’’ and ‘‘f’’ [74].
The PCR protocol included a 4 min initial denaturation (96uC)
and 32 cycles of 1 min denaturation (96uC), 1 min annealing
(54uC), 1 min elongation (72uC) and final elongation of 7 min at
72uC. The barcoding fragment of matK was amplified with primers
X and 3.2 [75]. The PCR protocol included a 1 min initial
denaturation (96uC) and 38 cycles of 30 s denaturation (96uC),
40 s annealing (46uC), 1 min elongation (72uC), with a final
elongation of 7 min at 72uC. The first half of rbcL was amplified
with primers rbcL1F and rbcL724R [76], following a protocol of
4 min initial denaturation (96uC), and 33 cycles of 1 min
denaturation (96uC), 1 min annealing (50uC) and 1 min 20s
elongation (72uC), with a final elongation of 7 min at 72uC.
Finally, the ndhF-rpL32 intergenic spacer was amplified with
primers ndhF and rpL32-R [69]. Due to amplification of non-target
product, we modified the PCR conditions given by [69] as follows:
one cycle of denaturation (96uC) for 2 min, 30 cycles of 95uC for
40 s, 52uC for 1 min and 65uC for 3 min 20 s with ramp of 0.3/s
to 65uC and a final elongation cycle of 65uC for 5 min. All
amplifications were performed in 30-mL volume reactions with
BioMix (Bioline Ltd. London, UK).
PCR purification and DNA sequencing of both strands were
performed by Macrogen Inc. (Seoul, Korea). Complementary
strands were assembled and edited with EditSeq (DNASTAR,
Madison, WI). Alignments for rbcL and matK sequences were
performed manually in BioEdit v. 7.0. ITS2, and the trnL-F and
ndhF-rpL32 intergenic spacer sequences were aligned using
CLUSTAL W [77], and adjustments were made manually in
BioEdit v. 7.0, following the guidelines of Kelchner [78]. All newly
generated sequences have been submitted to GenBank (see Tables
S2 and S3) and the data matrix and phylogenetic tree generated
here are available on TreeBase (www.treebase.org) under the
accession number 11586.
Phylogenetic analyses and manipulations
Sequence data were analysed under the Maximum Likelihood
(ML) criterion, with RAxML [79] using the partitioned model
option with the GTR+C model and running 1000 bootstrap
replicates [80].
We borrowed two metrics from community ecology phyloge-
netics in order to assess and detect phylogenetic signal in medicinal
properties. The first was the ‘‘comstruct’’ option in Phylocom 4.1
[81]. This metric assesses the significance of phylogenetic signal for
a community of taxa, which is the subset of a phylogeny. In other
words, it calculates how significantly a group of species are
clumped on the phylogeny. To do this, the mean phylogenetic
distance (MPD) and mean nearest phylogenetic taxon distance
(MNTD) for each sample (group of species on the phylogeny) is
calculated and they are compared to MPD/MNTD values for
randomly generated samples to provide p values for the
significance of phylogenetic signal for the given sample (p values
are calculated based on the frequency of random samples that
were more clumped on the phylogeny than the real sample). For
this study, we compiled ‘‘communities’’ of taxa that are used for
one of the categories of use. This means that instead of grouping
taxa based on which ecological zone or geographical area they are
found, we grouped taxa that have similar uses in medicine together
under one ‘‘community’’. This way, we are able to assess the
phylogenetic signal of each category of use on the phylogeny of
Pterocarpus and answer the question: Are taxa used for a certain
category more significantly related than expected by chance alone?
Phylogenetic Ethnobotany of Pterocarpus
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The second metric used was the command ‘‘nodesig’’ in
Phylocom v 4.1 [81]. This option uses the same community
sample as described above and tests each node of the phylogeny
for overabundance of terminal taxa distal to it. Observed patterns
for each sample are compared to those from random samples to
provide significance for the observed overabundance. For a node
that is identified through this approach, the descendants of this
node are significantly more likely to belong to the ‘‘community’’
under consideration that expected by chance alone. As mentioned
earlier, a ‘‘community’’ for this study represents the group of
species used for a certain category of use. Hence, this technique
identifies the exact position of phylogenetic clumping on the
phylogeny, namely the ‘‘hot’’ nodes for a category of use. This can
help us assess the predictive power of the phylogeny for the
discovery of new medicinal species.
The rationale behind using these metric is as follows: If a certain
category of use shows strong phylogenetic signal, then closely
related species demonstrate similar uses. With the first metric, we
can asses which categories of use demonstrate strong phylogenetic
signal. For these categories of use, we can subsequently identify
which nodes on the phylogeny have more medicinal taxa than
expected by chance, using the second tool. Taxa descending from
these nodes are the ones that show significant ‘‘overabundance’’ in
medicinal properties. Therefore, they deserve further investiga-
tion, including those species that are not reported in traditional
medicine, as they are likely to share these properties with their
relatives, as shown in Figure 2. The matrix showing the samples
used for all Phylocom analyses is given in Table S4.
Analyses using these two approaches were carried out for each
of the 13 categories of use mentioned above. Additionally, we
performed the same analyses for three diseases of particular
interest for which there is experimental evidence of bioactivity of
Pterocarpus species: diabetes, malaria and cancer [82,83,84,85,86,
87,88,89,90,91,92,93]. This also allowed a test of our methods at
different levels of ethnomedicinal specificity (condition versus
group of conditions).
Results
Ethnomedicinal review
Medicinal properties found in the literature for Pterocarpus
species are shown in Table S1. Nineteen taxa are found with some
medicinal applications and the species with the greatest numbers
of reported uses are the African P. erinaceus (65), P. angolensis (56), P.
soyauxii (37) and the Indomalayan P. santalinus (43) and P. indicus
(32). As shown in Figure 3, Pterocarpus species are mainly used for
Gastro-intestinal and Skin problems but they also have wide
applications for Genito-urinary/Fertility and Respiratory condi-
tions. Anti-inflammatory and poison remedies are the least
common. The usage patterns of Pterocarpus species are fairly
similar across all three regions (Neotropics, Tropical Africa and
Indomalaya) of the pantropical range of the genus. For example,
Gastro-intestinal and Skin remedies are consistently the most
common, while Inflammation Nervous and Pain treatments are
the least common in all three regions (Figure 4). One of the most
profound differences between the three regions is the heavy use of
neotropical taxa to treat Infections/Fever and their low contribu-
tion to Genito-urinary treatments, one of the most common uses in
tropical Africa and Indomalaya.
Phylogenetic analyses
The matrix included 75 taxa, 68 of which were Pterocarpus taxa
and seven were closely related genera. The total length of the
aligned matrix was 3,592 bp. Phylogenetic reconstruction analysis
with RAxML produced the phylogenetic tree shown in Figure 5.
Pterocarpus acapulcensis, weakly resolved with the outgroup mono-
specific genus Maraniona, is placed in a sister relationship with the
rest of the genus. The rest of the genus is divided into two large
clades, one comprising the species complex P. rohrii and the rest of
the neotropical taxa (BP 100) and the other including all African
and Indomalayan taxa (BP 93), the latter nested within the
African grade (Figure 5). Several species are not recovered as
monophyletic, although most without strong support, except for
P. rohrii.
Phylogenetic manipulations
The assessment of phylogenetic signal, recovered with the
‘‘comstruct’’ tool, is shown in Table 1. Medicinal usage overall was
not phylogenetically clumped, meaning that Pterocarpus species
used medicinally are not found in a certain lineage, but are
distributed all over the phylogeny of the genus. However, when
the usage was organised in categories we observed some cases of
strong phylogenetic signal. The only category of use that showed
significant phylogenetic clumping with the MPD was Musculo-
skeletal. In contrast, there were six uses (Inflammation, Musculo-
Skeletal, Pain, Sensory, Skin and Malaria) that demonstrated
significant phylogenetic signal with the MNTD (Table 1).
The nodes that demonstrated significant overabundance in
medicinal species with the ‘‘nodesig’’ command in Phylocom v4.1
for Inflammation, Musculo-Skeletal, Pain, Sensory, Skin and
Malaria uses are shown in Table 2. With few exceptions, most of
Figure 2. Two different scenarios for the distribution of medicinal uses on a hypothetical phylogeny. In both cases there are three
medicinal taxa, designated at the tips of the tree. A: There is no significant phylogenetic signal as the taxa are overdispersed. B: The phylogenetic
signal is strong as three of the four closely related species are used and the node indicated with ‘‘*’’ shows significant overabundance in medicinal
species. In the first case phylogeny cannot act as a guide for discovery of medicinal species. In the second case the species marked with ‘‘?’’
potentially shares medicinal properties with its close relatives.
doi:10.1371/journal.pone.0022275.g002
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the nodes are located in the clade comprising the African and the
Indomalayan species and there is great overlap in the ‘‘overabun-
dant’’ nodes across the uses.
Discussion
In this study we produced an ethnomedicinal review for the
genus Pterocarpus (Table S1) and reconstructed the relationships
between all Pterocarpus species, presenting a well supported
molecular multi-locus phylogeny for the genus (Figure 5). Using
these tools, we assess the proposed application of phylogenetics to
bioscreening and ethnobotany [12,13,14,15] and devise meaning-
ful tools that can predict the phylogenetic position of species with
high medicinal potential. Some of the phylogenetic relationships
recovered here have been hypothesised based on morphological
affinities, adding support to our results. These include the
proximity between Pterocarpus mildbraedii and P. officinalis, P.
amazonum and P. santalinoides, P. brenanii and P. rotundifolius [52],
P. monopyllus and P. ternatus [61] and between the five Indomalayan
species [52]. As mentioned above it has, however, long been
suspected that several Pterocarpus species are paraphyletic - e.g. the
Neotropical species Pterocarpus rohrii of which the samples included
in this study are found in scattered position across the Neotropical
clade. Recognising the necessity for well-circumscribed taxonomic
entities in useful plants groups, one of us (BBK) is currently
undertaking a taxonomic revision of Pterocarpus.
In terms of ethnomedicinal uses, our results from an extensive
literature review indicate that Pterocarpus is a very valuable genus in
traditional medicine, as almost two thirds of the taxa are used
throughout the range of the genus and for multiple uses. Although
we found usage under several of the categories suggested by [56],
Pterocarpus species are mainly used for Gastro-intestinal and Skin
afflictions but they also have wide applications for Genito-urinary/
fertility and respiratory conditions, as shown in Figure 3. The well
supported phylogeny of all species in Pterocarpus, along with its
richness in medicinal uses, provided a suitable model to test
phylogenetic patterns in medicinal properties and allowed us to
perform explicit phylogenetic tests.
We detected strong phylogenetic signal in medicinal usage in
several cases, indicating that medicinal properties in the genus are
not distributed evenly across the phylogeny, but are rather
clumped, as was suggested in previous studies of other groups at
different hierarchical levels (genus [13,14] and flora [15]). More
specifically, usage for inflammations, musculo-skeletal afflictions,
pain, sensory and skin problems, as well as malaria, demonstrated
significant clumping on the phylogeny (Table 1). Although most of
these categories were the ones with few uses, they also include uses
for skin problems, the second most commonly encountered
category (Figure 3). As shown in Table 1, phylogenetic signal
was recovered mainly using the MNTD and not the MPD, where
significant signal was found for one category of use only. These
two values both measure phylogenetic clumping, however at
different hierarchical levels. With the MPD measure, one can
detect phylogenetic signal in deep nodes of the phylogeny, whereas
with the MNTD clumping is measured towards the tips of the
phylogenetic tree [94]. In advising bioscreening schemes, one
Figure 3. Number of uses per category of use for Pterocarpus species.
doi:10.1371/journal.pone.0022275.g003
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would like to narrow down selection of putatively useful species to
a small number. Therefore, indentifying clumping in deeper nodes
of the phylogeny is probably not useful, as deep nodes define
clades with numerous species, which means informed and well-
defined decisions cannot be made for bioscreening. Thus,
clumping toward the tips of the phylogeny (MNTD) is more
relevant to bioscreening.
It has been proposed that cross-cultural agreement in plant
usage implies bioactivity as independent discovery in disparate
cultures should have an empirical basis [9,95,96,97,98]. Even
without taking phylogenetic relationships into account, a degree of
agreement among different ethnomedicinal systems is evident.
Figure 4 shows that Pterocarpus species are used to treat similar
conditions in the Neotropics, Tropical Africa and Indomalaya.
Given the geographical distance of these three regions and the
disparate cultures found there, it is very likely that this parallel
usage is the product of independent discoveries, which demon-
strates the efficiency of local cultures in identifying plants with
relatively similar chemical profiles (the three biogeographical
clades within Pterocarpus) to treat similar conditions. Undoubtedly,
cultural exchange has taken place to a certain degree between
these regions. For example, uses of Ocimum species have been
recorded in Afro-Brazilian communities, attributed to traditional
uses in Africa [99]. Although we acknowledge the possibility that
common patterns might be due to cultural exchange, given the
large geographic scale of this study, we believe such cases are the
exception, rather than the rule. However, we recognise that
common ethnobotanical trends, even when independent, might
not be the result of underlying bioefficacy in every case. Plant use
is often guided by a ‘‘doctrine of signatures’’, the belief that a plant
possess medicinal properties due the presence of physical attributes
(colour, scent, shape) [100,101]. The yellow flowers and red sap
found in Pterocarpus species could be a reason of their applications
in urinary and blood disorders. Nevertheless, despite all these
possible alternative explanations as to how cross-cultural ethno-
botanical patterns arise, we show that phylogenetic interpretation
of such patterns allows us to address traditional questions in
ethnobotany from novel perspectives.
The two amphiatlantic species (P. officinalis and P. santalinoides)
provide an excellent system to study the use of the same species in
notably different medicinal systems, in the light of phylogeny and
biogeography. As Figure 5 shows, P. officinalis dispersed from West
Africa to the Neotropics, as the neotropical subspecies (P. officinalis
subsp. officinalis) is nested in an African clade, while P. santalinoides
dispersed from the Neotropics to West Africa, as the African
samples are nested in the neotropical clade. Interestingly, both
taxa have more uses in the ‘‘new’’ regions than in their regions of
origin and we attribute this pattern to phylogenetic structure. We
recorded no uses for P. officinalis in Africa and six uses in the
Neotropics. Similarly, we found one use for P. santalinoides in the
Neotropics and 22 in Africa. These species, by having no close
relatives in the new regions, contribute novel phylogenetic
diversity, and hence possibly novel medicinal properties, to these
areas. On the contrary, in the region of origin, close relatives with
Figure 4. Relative usage per category of use for Pterocarpus in the Neotropics, Tropical Africa and Indomalaya.
doi:10.1371/journal.pone.0022275.g004
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similar phytochemical profiles are available. For example, P.
santalinoides is used for malaria in West Africa, but not in the
Neotropics, where its close relatives P. amazonum and P. rohrii are
used (Table S1). Similarly, P. officinalis is used in the Neotropics as
an astringent, however that use is replaced in Africa, where it is
very narrowly distributed, by P. angolensis and P. erinaceus, the latter
being sympatric to P. officinalis. Moreover, we found common
amphiatlantic use for P. santalinoides as a poison antidote. Such
Figure 5. ML phylogenetic tree of Pterocarpus species and allies. The tree was reconstructed with RAxML and using all DNA markers (nrITS2,
rbcL, matK, trnL and ndhF-rpL32). Numbers above branches show bootstrap percentages (BP). Distributions of the main clades are on the right.
doi:10.1371/journal.pone.0022275.g005
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agreement in use has been found to be strongly linked to
pharmacological activities at this taxonomic level [97].
Just as knowledge of phylogeny informs the interpretation of
ethnobotanical use at the species level, confidence in inferences of
bioactivity is increased when clades sharing specific ethnomedic-
inal uses are distributed across regions. For example, Figure 6
shows that the larger of the clades showing use in treating malaria
and musculo-skeletal disorders is distributed in Tropical Africa
and Indomalaya. As we discuss below, clades which encompass
many species for a specific use can become targets for future
screening. When these clades are distributed across regions, it
seems more probable that selection for ethnomedicinal use reflects
underlying activity, and not a preference within a culture for using
species which might share particular attributes such as similar
overall morphology, because of shared ancestry.
Regarding ethnopharmacology and bioscreening, there are
three ways in which our results can be of use. First, as proposed in
earlier investigations, close relatives of species with known
bioactivity can be prioritised for screening for similar activity
[12,13]. For example, the species P. santalinus and P. marsupium are
very well known species in traditional medicine, especially for their
use to treat diabetes [102,103,104,105]. Both species have been
studied in vitro and have shown notable hypoglycaemic bioactivity
[87,88,90,91,92,93]. However, P. santalinus is listed as endangered
and P. marsupium as vulnerable on the IUCN Red List [55] and the
former is also included in CITES Annex II, therefore their use in
medicine is not recommended as overharvesting could pose
further threat to their survival. Pterocarpus dalbergioides, a stenoen-
demic of the Andaman Islands, has been shown to possess similar
bioactivity [89], however its narrow range would not support
sustainable harvesting either. Although the use for diabetes does
not demonstrate significant phylogenetic structure on the phylog-
eny (Table 1), these results suggest that hypoglycaemic bioactivity
is shared by all species in the clade defined by the MRCA of
P.marsupium1-P.dalbergioides, which includes P. macrocarpus and P.
indicus that are widespread in Southeast Asia [52]. We propose that
Table 1. Significance (p values) of phylogenetic clumping of
medicinal usage of Pterocarpus species, assessed with the
‘‘comstruct’’ option in Phylocom v4.1.
Category of use p value (MPD) p value (MNTD)
Medicinal uses overall .0.05 .0.05
Circulatory/Blood .0.05 .0.05
Gastro-intestinal .0.05 .0.05
Genito-urinary/Fertility .0.05 .0.05
Infections/Fevers .0.05 .0.05
Inflammation .0.05 ,0.05
Musculo-skeletal ,0.05 ,0.01
Nervous .0.05 .0.05
Pain .0.05 ,0.05
Poisons treatment .0.05 .0.05
Respiratory .0.05 .0.05
Sensory .0.05 ,0.05
Skin .0.05 ,0.05
Unspecific .0.05 .0.05
Diabetes .0.05 .0.05
Malaria .0.05 ,,0.01
Cancer .0.05 .0.05
Numbers in bold indicate cases where significant phylogenetic signal was
recovered.
doi:10.1371/journal.pone.0022275.t001
Table 2. Nodes recovered as significantly overabundant in
medicinal species in the Pterocarpus phylogeny, as assessed
with the ‘‘nodesig’’ option in Phylocom v4.1.
Category of use node defined as the MRCA* of
Inflammation P.lucens_antunesii-P.dalbergioides
Inflammation P.mildbraedii_usambarensis-P.dalbergioides
Inflammation P.osun-P.dalbergioides
Inflammation P.angolensis2-P.dalbergioides
Inflammation P.angolensis2-P.erinaceus1
Inflammation P.soyauxii2-P.dalbergioides
Inflammation P.marsupium3-P.santalinus2
Musculo-skeletal P.lucens_antunesii-P.dalbergioides
Musculo-skeletal P.mildbraedii_usambarensis-P.dalbergioides
Musculo-skeletal P.osun-P.dalbergioides
Musculo-skeletal P.angolensis2-P.dalbergioides
Musculo-skeletal P.angolensis2-P.erinaceus1
Musculo-skeletal P.soyauxii2-P.dalbergioides
Musculo-skeletal P.marsupium3-P.santalinus2
Pain P.lucens_antunesii-P.dalbergioides
Pain P.mildbraedii_usambarensis-P.dalbergioides
Pain P.osun-P.dalbergioides
Pain P.angolensis2-P.dalbergioides
Pain P.angolensis2-P.erinaceus1
Pain P.soyauxii2-P.dalbergioides
Pain P.marsupium1-P.dalbergioides
Pain P.marsupium3-P.santalinus2
Sensory P.lucens_antunesii-P.dalbergioides
Sensory P.mildbraedii_usambarensis-P.dalbergioides
Sensory P.osun-P.dalbergioides
Sensory P.osun-P.tinctorius_"albopubescens"
Sensory P.tinctcorius_"holtzii"-P.tinctorius_"albopubescens"
Sensory P.angolensis2-P.dalbergioides
Sensory P.angolensis2-P.erinaceus1
Sensory P.marsupium1-P.dalbergioides
Sensory P.marsupium3-P.santalinus2
Skin P.mildbraedii_usambarensis-P.dalbergioides
Skin P.osun-P.dalbergioides
Skin P.osun-P.tinctorius_"albopubescens"
Skin P.tinctorius_"holtzii"-P.tinctorius_"albopubescens"
Skin P.angolensis2-P.dalbergioides
Malaria P.osun-P.dalbergioides
Malaria P.angolensis2-P.dalbergioides
Malaria P.angolensis2-P.erinaceus1
Malaria P.marsupium3-P.dalbergioides
Malaria P.macrocarpus-P.dalbergioides
Malaria P.indicus1-P.dalbergioides
Malaria P.rohrii_"steinbachianus"-P.amazonum1
Malaria P.rohrii4-P.amazonum2
*Most Recent Common Ancestor.
doi:10.1371/journal.pone.0022275.t002
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these widespread species be investigated for hypoglycaemic
bioactivity to investigate whether they can substitute the use of the
more endangered relatives. Should these species prove to share this
bioactivity as we predict here, their application will not only provide
new medicinal species, but will also assist the conservation of the
more restricted and endangered species that are currently used.
Figure 6. Phylogeny of Pterocarpus with clades that show significant overabundance in medicinal species highlighted. Results were
recovered using the ‘‘nodesig’’ option in Phylocom v 4.1. A: species to treat malaria. B: species to treat musculo-skeletal conditions. Although some
clades are used for a variety of conditions, different properties are found in different parts of the phylogeny.
doi:10.1371/journal.pone.0022275.g006
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Second, in the case of absence of pharmacological data,
phylogenetic signal can provide indirect evidence of underlying
bioactivity. If closely related species share similar ethnomedicinal
properties (which can be interpreted as a case of phylogenetic
conservatism [10,11]), it is very likely that this reflects the
underlying bioactivity of these species. For example, the clade
comprising species from Africa and Indomalaya is the richest in
medicinal properties. The species with the highest numbers of
uses, namely P. erinaceus (65), P. angolensis (56), P. santalinus (43), P.
soyauxii (37) and P. indicus (32) are all included in the clade defined
by the MRCA of P.angolensis2-P.dalbergioides (Figure 5) that is often
recovered among the nodes that show significant phylogenetic
overabundance for different uses (Table 2). These species and their
close relatives are therefore considered to be of high potential for
bioprospecting. What is particularly interesting in this clade is that
it is distributed in two large biogeographic regions, where very
different human cultures are found and it is relatively safe to
assume that any common ethnobotanical patterns observed in the
two regions were discovered independently and are not due to
shared cultural history. Therefore, not only does this clade
demonstrate phylogenetic conservatism [10,11] in medicinal
usage, but it also demonstrates cross-cultural agreement in usage
(Figure 4 and 6), which has been used as a criterion to imply
bioactivity [9,95,106,107]. These two criteria provide multiple
lines of evidence pointing towards the bioactivity in this clade,
especially for the conditions where significant clumping was
observed (inflammations, musculo-skeletal afflictions, pain, sensory
and skin problems, as well as malaria; Table 1).
Third, a more sophisticated approach is to identify nodes on the
phylogeny that have high potential for bioscreening. We
demonstrated that with the tool ‘‘nodesig’’ in Phylocom the exact
phylogenetic position of overabundance in medicinal properties
can be recovered. For example, several Pterocarpus species are being
used to treat malaria (Table S1) and our results show that the
species used in such applications are significantly clumped on the
phylogeny (Table 1), suggesting that phylogenetic proximity is a
good proxy for antiplasmodial bioactivity. We can subsequently
identify the nodes that are significantly overabundant in
‘‘antimalarial’’ species. These are given in Table 2 and also
shown highlighted in Figure 6. As shown, there are two positions
in the phylogeny that are overabundant in species with
antimalarial activity and they cover all three regions of the range
of the genus, again showing both phylogenetic conservatism and
cross-cultural usage as evidence for bioactivity.
The first clade is a neotropical clade that includes P. amazonum,
some P. rohrii samples and P. santalinoides, the last also found in
West Africa. All three species are reported with demonstrable in
vitro use against malaria [83,84,86]. The bioactivity for the
amphiatlantic P. santalinoides was demonstrated for West African
material [84], however as we show here, South American material
is extremely likely to share these properties as it falls within this
clade and we propose it be further investigated. Pterocarpus rohrii is
an extremely variable and widespread species, found throughout
South and Central America. The results from this study, which has
sampled material across the species range, reveal the polyphyly of
this species and show that phylogenetic units within the species
show geographic structure (Figure 5) suggesting that its taxonomy
should be revised. The samples in this ‘‘antimalarial’’ clade are
from South America and bioactivity has been demonstrated for
South American material only [83]. Based on our results, material
of P. rohrii from this clade is more valuable as antimalarial, as the
other lineages of P. rohrii are not recovered significantly
overabundant in antimalarial use. Although it is not unlikely that
this species possesses bioactivity throughout its range, but it is
simply not used across its range due to differences in ethnome-
dicinal floras in different cultures, it is also possible that
antimalarial activity is present in this clade only. Further research
in this species on material from different localities is needed to
establish whether antimalarial properties are present across its
range. Nonetheless, the combination of traditional knowledge and
phylogenetic information has already brought to light cryptic
diversity demonstrating to be a valid approach to elucidating
taxonomy [108] and we believe that such information could be
incorporated in a taxonomic revision of P. rohrii, as it could clarify
which taxonomic units are more valuable in ethnomedicine.
The second antimalarial clade includes all species defined by the
MRCA of P. osun and P. dalbergioides (Table 2). Nevertheless, the
only species in this clade that have reported antimalarial uses are
P. angolensis, P. erinaceus (also in vitro), P. indicus and P. macrocarpus.
This renders all other species in the clade, namely P. dalbergioides, P.
marsupium, P. osun, P. santalinus, P. soyauxii, P. tessmanii and P.
tinctorius very good candidates for antiplasmodial activity. Out of
these, of particular interest are P. soyauxii and P. tinctorius, as they
are widespread in Africa, material availability will be greater and
no harvesting pressure will be posed to narrowly distributed or
endangered species. The phylogenetic position of the former,
which is closely related to P. angolensis, P. erinaceus, as well as to P.
indicus and P. macrocarpus (Figure 5) makes it a better candidate.
Furthermore, we predict that P. angolensis, already used tradition-
ally as an antimalarial, will very likely share the in vitro activity of its
sister species P. erinaceus.
Conclusions
This, to the best of our knowledge, is the first multidisciplinary
study that draws on four different sources (using taxonomic,
phylogenetic, biogeographic and ethnobotanical information) to
provide new perspectives on bioactivity in plants, based on the
criteria of cross-cultural usage and phylogenetic conservatism
across different biogeographic regions. Our study demonstrates
that phylogeny and biogeography can be used as novel tools in
ethnobotany to interpret processes that shape traditional usage
and particularly cross-cultural patterns and our community
phylogenetic approach demonstrates that similar ethnobotanical
uses can arise in parallel in different areas when related plants are
available there.The advent of molecular phylogenetics heralded a
much deeper understanding of organismal relationships. Phyloge-
netic tools entered several disciplines to provide explanatory power
and recover patterns previously undetected. Molecular data are
becoming increasingly available in recent years, especially with the
rapid development of next-generation sequencing techniques. At
the same time, ethnomedicinal and ethnopharmacological infor-
mation has also been accumulating over the last decades,
providing invaluable insight into the use of nature by humans in
traditional medicine. We demonstrated here that the combination
of information from these fields using quantitative metrics is
particularly meaningful and opens up new opportunities for
further biological studies through its potential to direct bioscreen-
ing studies, but also enables insights into processes that shape
ethnobotanical knowledge. With molecular and ethnomedicinal
data publicly available and readily accessible, the potential for
them to be combined and reanalysed reciprocally is immense.
These approaches could be developed even further than in this
study. For example, ethnomedicinal metrics of confidence in plant
use (relative cultural importance index [109], or informant
consensus [98]) can be mapped on phylogeny to provide even
greater explanatory power. The methods proposed here can be
applied to other organisms, at different hierarchical levels (family,
infraspecific [110,111]), sample regions and also for other
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properties, such as the search for new food plants [112], plants
with economical potential [15], or new chemical compounds for
medicine or pesticides [25,26,27,113]. Future analyses can include
ecological data that can predict in a phylogenetic context which
areas harbour medicinal species diversity (medicinal hotspots).
Phytochemical and ethnomedicinal data can be combined on
phylogenies to test how well they can provide reciprocal
illumination. Furthermore, similar studies can further our
understanding of cultural processes that shape ethnobotanical
knowledge, as phylogenetic similarity can be added as an extra
parameter in cross-cultural comparisons of ethnomedicinal
systems in order to provide greater insight into usage in different
cultures.
Although ethnobotanically directed screening was proposed as a
promising way of enhancing rates of bioprospecting schemes and
several studies have shown that can lead to more positive hits
compared to random sampling [3,114], there are several reasons
why these approaches are not likely to lead directly to new
pharmaceutical drugs [115]. However, our study can serve as an
example of how understanding patterns of successful traditional
medicine can help promote local economic development through
trade [116] appreciation of traditional medicine by the scientific
community [117] and, most importantly, enhance local commu-
nity health [118]. We would like to conclude with a reflection
upon the ethical questions that arise where phylogenetic
ethnobotany results in recovering successful traditional medicines.
International legal frameworks, such as the one established by the
Convention of Biological Diversity, safeguard the intellectual
property of cultures and individuals with specialist knowledge.
Profitable results from any such investigations should not only be
profitable for both parts (investigators and people with knowledge),
but must also focus on alleviating those people’s livelihoods and
enhance their healthcare [119]. A mechanism of benefit sharing is
needed for cases where new medicinal plant discoveries that are
not traditionally used in some culture but are based on traditional
knowledge of species that are closely related to them.
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